Correction to: 2023 Scientific Sessions Abstract 14413

a correction notice is needed.The Results section read: Of 2,922,522 individuals who met inclusion criteria, 998,234 (34%) were eligible for AOM (mean age, 49 years; 53% female).Of these, 30%, 41%, 18%, and 11% had a BMI (kg/m 2 ) of 27-29.9,30-34.9,35-39.9, and ≥40, respectively.Prior metabolic/bariatric surgery was seen in 2.3%.Musculoskeletal disorders (54%), dyslipidemia/hyperlipidemia (35%), and hypertension (32%) were the most common ORCs, with ≥2 ORCs observed in 58%.Prescription of any FDA-approved AOM was observed in only 1.2% of all eligible patients.Liraglutide 3.0 mg (58% of all AOM) was the most prescribed AOM.AOM prescriptions increased modestly with higher BMI, ORC burden, and number of CVD risk factors (Figure).Among those with prior MACE (11%), 1.5% (1.0% if without T2DM) were prescribed FDAapproved AOM.It has been updated to read: Of 2,469,473 individuals who met inclusion criteria, 1,111,396 (44%) were eligible for AOM (mean age, 54 years; 57% female).Of these, 31%, 41%, 17%, and 11% had a BMI (kg/m 2 ) of 27-29.9,30-34.9,35-39.9, and ≥40, respectively.Prior metabolic/bariatric surgery was seen in 1%.Musculoskeletal disorders (54%), dyslipidemia/hyperlipidemia (36%), and hypertension (35%) were the most common ORCs, with ≥2 ORCs observed in 62%.Prescription of any FDA-approved AOM was observed in only 1.4% of all eligible patients.Liraglutide 3.0 mg (46% of all AOM) was the most prescribed AOM.AOM prescriptions increased modestly with higher BMI, ORC burden, and number of CVD risk factors (Figure).Among those with prior MACE (9%), 1.2% (1.0% if without T2DM) were prescribed FDA-approved AOM.